Yutaka Seino

发表

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg

Y. Terauchi, H. Miyoshi, Keiji Nishijima, 2022, Journal of diabetes investigation.

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study

Y. Seino, K. Kaku, S. Hiroi, 2012, Diabetes, obesity & metabolism.

Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial (EMPA‐ELDERLY)

D. Yabe, T. Meinicke, Gosuke Homma, 2023, Diabetes, obesity & metabolism.

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.

Y. Seino, M. Zdravkovic, K. Kaku, 2008, Diabetes research and clinical practice.

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

Y. Seino, K. Kaku, M. Rasmussen, 2010, Current medical research and opinion.

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetes

P. Clauson, Y. Seino, K. Kaku, 2010, Diabetes, obesity & metabolism.

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)*

Y. Seino, K. Min, A. Takami, 2012, Diabetes, obesity & metabolism.

Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study

Yuichiro Yamada, D. Yabe, Y. Seino, 2021, Journal of diabetes investigation.

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia

L. Niskanen, K. Khunti, M. Nangaku, 2023, Cardiovascular Diabetology.

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label long‐term extension study

Y. Seino, K. Kaku, S. Hiroi, 2011, Diabetes, obesity & metabolism.

Physiology of GIP - A Lesson from GIP Receptor Knockout Mice

Y. Seino, Y. Yamada, Yutaka Seino, 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Efficacy and Safety of 6-Month High Dietary Protein Intake in Hospitalized Adults Aged 75 or Older at Nutritional Risk: An Exploratory, Randomized, Controlled Study

Yuichiro Yamada, Hiroto Honda, S. Fujita, 2023, Nutrients.

Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs

D. Yabe, T. Kurose, H. Kuwata, 2014, Diabetes, obesity & metabolism.